Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Sarcoma 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Ichthyosis, X-Linked 1Glioma 1

Interventions

Temozolomide 109Magnetic Resonance Spectroscopy 52Bevacizumab 52Radiotherapy 44Irinotecan 27Blood Specimen Collection 19Surgical Procedures, Operative 16Radiation 15Aminolevulinic Acid 15Carboplatin 13fluorodopa F 18 12Nivolumab 12Radiotherapy, Intensity-Modulated 11Carmustine 11Radiosurgery 10Magnetic Resonance Imaging 10pembrolizumab 9Topotecan 9Specimen Handling 9Everolimus 9Erlotinib Hydrochloride 9Biopsy 9poly ICLC 8Surveys and Questionnaires 8Standard of Care 8Etoposide 8Drug Therapy 8Lomustine 7Filgrastim 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioma × ADI PEG20 × Clear all
NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡